
Securing Access to Oral AML Therapy: Formularies, Prior Authorization, and Copays
Adding oral agents to hospital formularies speeds initiation but creates financial risk, and even dedicated access teams struggle against prior authorization delays, steep copays, and automated denials.
Episodes in this series

In "Securing Access to Oral AML Therapy: Formularies, Prior Authorization, and Copays," the panel explores the institutional effort required to get oral AML drugs to patients without interruption.
Dr. Mahmoudjafari notes that payers may not share clinicians' urgency about leukemia. She asks Dr. Stein how his team ensures uninterrupted access to oral agents before and during hospitalization. Dr. Stein explains that newly diagnosed inpatients once waited while prescriptions were filled at an outside or institutional specialty pharmacy, delivered, and processed for copay assistance. His center asked its pharmacy and therapeutics committee to add venetoclax to the inpatient formulary. Formulary status creates its own risk. If a physician prescribes it off label and insurance denies outpatient coverage, the cancer center may absorb the ongoing cost. His center now strictly limits prescribers. Pharmacy confirms use only for FDA-approved or NCCN category 2A or higher indications.
For outpatient access, Dr. Stein credits a dedicated team, including prior authorization staff, pharmacists who help with appeal letters, and copay assistance specialists. Even so, outcomes are inconsistent. He describes a patient starting cycle 2 of hypomethylating agent plus venetoclax who cannot obtain venetoclax because of copay challenges. Dr. Mahmoudjafari shares that her institution also added venetoclax to formulary to avoid treatment delays. It restricts inpatient use to newly diagnosed patients and requires an active outpatient authorization, so supply is not cut off after discharge. She calls the coordinated effort gargantuan and increasingly complex. Copay foundation grants can run out in the first month of the year, leaving patients without support.
Dr. Stein then raises a newer dynamic: artificial intelligence in medical billing disputes. He admits he now uses AI to draft his own appeal letters, which he finds quite effective. On the other side, payers deploy AI agents that scan those appeals for grounds to deny. He expects both sides to keep escalating and soon outperform the humans involved. Dr. Mahmoudjafari agrees the field is in for an interesting contest.
Our next episode, "Transitioning to All-Oral AML Therapy: Prior Authorization Pearls and Copay Timing," turns to Dr. Murthy's approach to bridging patients onto oral therapy and Dr. Zeidan's prior authorization pearls.
Related to this article








